High-dose mitotane strategy in adrenocortical carcinoma: Prospective analysis of plasma mitotane measurement during the first 3 months of follow-up

European Journal of Endocrinology

Volumn 166, Issue 2, 2012, Pages 261-268

  Mauclère Denost, Sophie ^a,b   Leboulleux, Sophie ^a,b   Borget, Isabelle ^a   Paci, Angelo ^a,b   Young, Jacques ^b,c,d,e   Al Ghuzlan, Abir ^a   Deandreis, Desiree ^a,b   Drouard, Laurence ^a,b   Tabarin, Antoine ^f   Chanson, Philippe ^b,c,d,e   Schlumberger, Martin ^a,b,c   Baudin, Eric ^a,b,d  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c Hopitaux Universitaires Paris Sud   (France)

^d Institut National de la Santéet de la Recherche Médicale U693   (France)

^e Institut Gustave Roussy ^*  (France)

^f UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MITOTANE;

ABDOMINAL PAIN; ADRENAL CORTEX CARCINOMA; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; ATAXIA; BLOOD TOXICITY; CHOLESTASIS; CLINICAL ARTICLE; CLINICAL EVALUATION; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLYSIS; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; DYSARTHRIA; ERYTHROBLASTOPENIA; FEMALE; GASTROINTESTINAL TOXICITY; GYNECOMASTIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LEUKOPENIA; LIVER TOXICITY; MALE; MEMORY DISORDER; NAUSEA; NEUROTOXICITY; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; SKIN TOXICITY; TREATMENT DURATION; VERTIGO; VISUAL DISORDER; VOMITING;

ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BLOOD CHEMICAL ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MITOTANE; OSMOLAR CONCENTRATION; TIME FACTORS;

EID: 84856101843     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-11-0557     Document Type: Article

References (34)

1. Assie G, Antoni G, Tissier F, Caillou B, Abiven G, Gicquel C, Leboulleux S, Travagli JP, Dromain C, Bertagna X, Bertherat J, Schlumberger M & Baudin E. Prognostic parameters of metastatic adrenocortical carcinoma. Journal of Clinical Endocrinology and Metabolism 2007 92 148-154. (doi:10.1210/jc.2006- 0706)
2. Icard P, Goudet P, Charpenay C, Andreassian B, Carnaille B, Chapuis Y, Cougard P, Henry JF & Proye C. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World Journal of Surgery 2001 25 891-897. (doi:10.1007/s00268-001-0047-y)
3. Fassnacht M, Johanssen S, Fenske W, Weismann D, Agha A, Beuschlein F, Fuhrer D, Jurowich C, Quinkler M, Petersenn S, Spahn M, Hahner S & Allolio B. Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers. Journal of Clinical Endocrinology and Metabolism 2010 95 4925-4932. (doi:10.1210/jc.2010-0803)
4. Lughezzani G, Sun M, Perrotte P, Jeldres C, Alasker A, Isbarn H, Budaus L, Shariat SF, Guazzoni G, Montorsi F & Karakiewicz PI. The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation. European Journal of Cancer 2010 46 713-719. (doi:10.1016/j.ejca. 2009.12.007)
5. Berruti A, Fassnacht M, Baudin E, Hammer G, Haak H, Leboulleux S, Skogseid B, Allolio B & Terzolo M. Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel. Journal of Clinical Oncology 2010 28 e401-e402: (author reply e403). (doi:10.1200/JCO.2009. 27.5958)
6. Luton JP, Cerdas S, Billaud L, Thomas G, Guilhaume B, Bertagna X, Laudat MH, Louvel A, Chapuis Y, Blondeau P, Bonnin A &Bricaire H. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. New England Journal of Medicine 1990 322 1195-1201. (doi:10.1056/NEJM199004263221705)
7. Decker RA, Elson P, Hogan TF, Citrin DL, Westring DW, Banerjee TK, Gilchrist KW & Horton J. Eastern Cooperative Oncology Group study 1879: mitotane and adriamycin in patients with advanced adrenocortical carcinoma. Surgery 1991 110 1006-1013.
8. Pommier RF & Brennan MF. An eleven-year experience with adrenocortical carcinoma. Surgery 1992 112 963-970 (discussion 970-971).
9. Haak HR, Hermans J, van de Velde CJ, Lentjes EG, Goslings BM, Fleuren GJ & Krans HM. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. British Journal of Cancer 1994 69 947-951. (doi:10.1038/bjc.1994.183)
10. Barzon L, Fallo F, Sonino N, Daniele O & Boscaro M. Adrenocortical carcinoma: experience in 45 patients. Oncology 1997 54 490-496. (doi:10.1159/000227608)
11. Baudin E, Pellegriti G, Bonnay M, Penfornis A, Laplanche A, Vassal G & Schlumberger M. Impact of monitoring plasma 1,1- dichlorodiphenildichloroethane (o,p'DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 2001 92 1385-1392. (doi:10.1002/1097- 0142(20010915)92:6〈1385::AID-CNCR1461〉3.0.CO;2-2)
12. Williamson SK, Lew D, Miller GJ, Balcerzak SP, Baker LH &Crawford ED. Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study. Cancer 2000 88 1159-1165. (doi:10.1002/(SICI)1097-0142(20000301)88:5〈1159::AID-CNCR28〉3.0. CO;2-R)
13. Icard P, Chapuis Y, Andreassian B, Bernard A & Proye C. Adrenocortical carcinoma in surgically treated patients: a retrospective study on 156 cases by the French Association of Endocrine Surgery. Surgery 1992 112 972-979 (discussion 979-980).
14. Abiven G, Coste J, Groussin L, Anract P, Tissier F, Legmann P, Dousset B, Bertagna X & Bertherat J. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. Journal of Clinical Endocrinology and Metabolism 2006 91 2650-2655. (doi:10.1210/jc.2005-2730)
15. Wangberg B, Khorram-Manesh A, Jansson S, Nilsson B, Nilsson O, Jakobsson CE, Lindstedt S, Oden A & Ahlman H. The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane. Endocrine-Related Cancer 2010 17 265-272. (doi:10.1677/ERC-09-0190)
16. Malandrino P, Al Ghuzlan A, Castaing M, Young J, Caillou B, Travagli JP, Elias D, de Baere T, Dromain C, Paci A, Chanson P, Schlumberger M, Leboulleux S & Baudin E. Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma. Endocrine-Related Cancer 2010 17 797-807. (doi:10.1677/ERC-09-0341)
17. Nelson AA & Woodard G. Severe adrenal cortical atrophy (cytotoxic) and hepatic damage produced in dogs by feeding 2,2- bis(parachlorophenyl)-1,1- dichloroethane (DDD or TDE). Archives of Pathology 1949 48 387-394.
18. Bergenstal DM & Dao TL. Management of Addison's disease in adrenalectomized patients. Bulletin of the New York Academy of Medicine 1953 29 295-306.
19. van Slooten HMA, van Seters AP & Smeenk D. The treatment of adrenocortical carcinoma with o,p′-DDD: prognostic implications of serum level monitoring. European Journal of Cancer & Clinical Oncology 1984 20 47-53. (doi:10.1016/0277-5379(84)90033-6)
20. Terzolo M, Pia A, Berruti A, Osella G, Ali A, Carbone V, Testa E, Dogliotti L & Angeli A. Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer. Journal of Clinical Endocrinology and Metabolism 2000 85 2234-2238. (doi:10.1210/jc.85.6.2234)
21. Terzolo M, Angeli A, Fassnacht M, Daffara F, Tauchmanova L, Conton PA, Rossetto R, Buci L, Sperone P, Grossrubatscher E, Reimondo G, Bollito E, Papotti M, SaegerW, Hahner S, Koschker AC, Arvat E, Ambrosi B, Loli P, Lombardi G, Mannelli M, Bruzzi P, Mantero F, Allolio B, Dogliotti L & Berruti A. Adjuvant mitotane treatment for adrenocortical carcinoma. New England Journal of Medicine 2007 356 2372-2380. (doi:10.1056/NEJMoa063360)
22. Stigliano A, Cerquetti L, Borro M, Gentile G, Bucci B, Misiti S, Piergrossi P, Brunetti E, Simmaco M & Toscano V. Modulation of proteomic profile in H295R adrenocortical cell line induced by mitotane. Endocrine-Related Cancer 2008 15 1-10. (doi:10.1677/ERC-07-0003)
23. Abraham J, Bakke S, Rutt A, Meadows B, Merino M, Alexander R, Schrump D, Bartlett D, Choyke P, Robey R, Hung E, Steinberg SM, Bates S & Fojo T. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. Cancer 2002 94 2333-2343. (doi:10.1002/cncr.10487)
24. Faggiano A, Leboulleux S, Young J, Schlumberger M & Baudin E. Rapidly progressing high o,p'DDD doses shorten the time required to reach the therapeutic threshold with an acceptable tolerance: preliminary results. Clinical Endocrinology 2006 64 110-113. (doi:10.1111/j.1365-2265.2005.02403.x)
25. Moolenaar AJ, van Slooten H, van Seters AP & Smeenk D. Blood levels of o,p′-DDD following administration in various vehicles after a single dose and during long-term treatment. Cancer Chemotherapy and Pharmacology 1981 7 51-54. (doi:10.1007/BF00258213)
26. Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F, Terzolo M, Mueller HH, Hahner S & Allolio B. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification. Cancer 2009 115 243-250. (doi:10.1002/cncr.24030)
27. Hermsen IG, Fassnacht M, Terzolo M, Houterman S, den Hartigh J, Leboulleux S, Daffara F, Berruti A, Chadarevian R, Schlumberger M, Allolio B, Haak HR & Baudin E. Plasma concentrations of o,p′DDD, o,p′DDA, and o,p′DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. Journal of Clinical Endocrinology and Metabolism 2011 96 1844-1851. (doi:10.1210/jc.2010- 2676)
28. Daffara F, De Francia S, Reimondo G, Zaggia B, Aroasio E, Porpiglia F, Volante M, Termine A, Di Carlo F, Dogliotti L, Angeli A, Berruti A & Terzolo M. Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly. Endocrine-Related Cancer 2008 15 1043-1053. (doi:10.1677/ERC-08-0103)
29. Berruti A, Terzolo M, Sperone P, Pia A, Casa SD, Gross DJ, Carnaghi C, Casali P, Porpiglia F, Mantero F, Reimondo G, Angeli A & Dogliotti L. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocrine-Related Cancer 2005 12 657-666. (doi:10.1677/erc.1.01025)
30. Pohland RC & Counsell RE. The role of high density lipoproteins in the biodistribution of two radioiodinated probes in the rat. Toxicology and Applied Pharmacology 1985 77 47-57. (doi:10.1016/0041-008X(85)90266-2)
31. Carr BR, Parker CR Jr, Milewich L, Porter JC, MacDonald PC &Simpson ER. The role of low density, high density, and very low density lipoproteins in steroidogenesis by the human fetal adrenal gland. Endocrinology 1980 106 1854-1860. (doi:10.1210/endo-106-6-1854)
32. Gebhardt DO, Moolenaar AJ, van Seters AP, van der Velde EA &Gevers Leuven JA. The distribution of o,p′-DDD (mitotane) among serum lipoproteins in normo- and hypertriglyceridemia. Cancer Chemotherapy and Pharmacology 1992 29 331-334. (doi:10.1007/BF00685956)
33. Fassnacht M, Libe R, Kroiss M & Allolio B. Adrenocortical carcinoma: a clinician's update. Nature Reviews. Endocrinology 2011 7 323-335. (doi:10.1038/nrendo.2010.235)
34. Cazejust J, De Baere T, Auperin A, Deschamps F, Hechelhammer L, Abdel-Rehim M, Schlumberger M, Leboulleux S & Baudin E. Transcatheter arterial chemoembolization for liver metastases in patients with adrenocortical carcinoma. Journal of Vascular and Interventional Radiology 2010 21 1527-1532. (doi:10.1016/j.jvir.2010.05.020)